ArticlePloS one2026

A cost-effectiveness analysis comparing pembrolizumab combined with chemotherapy versus chemotherapy alone for advanced biliary tract cancer: US and China perspectives.

Chunhua Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.